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AbstrACt
Objective The aims of this paper were to identify, 
characterise and explain clinician factors that shape 
decision-making around antidepressant discontinuation in 
UK primary care.
Design Four focus groups and three interviews were 
conducted and analysed using thematic analysis.
Participants Twenty-one general practitioners (GPs), four 
GP assistants, seven nurses and six community mental 
health team workers and psychotherapists took part in 
focus groups and interviews.
setting Participants were recruited from seven primary care 
regions and two National Health Service Trusts providing 
community mental health services in the South of England.
results Participants highlighted a number of barriers 
and enablers to discussing discontinuation with patients. 
They held a range of views around responsibility, with 
some suggesting it was the responsibility of the health 
professional (HP) to broach the subject, and others 
suggesting responsibility rested with the patients. HPs 
were concerned about destabilising the current situation, 
discussed how continuity and knowing the patient 
facilitated discontinuation talks, and discussed how 
confidence in their professional skills and knowledge 
affected whether they elected to raise discontinuation in 
consultations.
Conclusions Findings indicate a need to consider support 
for HPs in the management of antidepressant medication 
and discussions of discontinuation in particular. They may 
also benefit from support around their fears of patient 
relapse and awareness of when and how to initiate 
discussions about discontinuation with their patients.
IntrODuCtIOn
Antidepressant prescriptions have risen 
steadily since the introduction of selective 
serotonin reuptake inhibitors (SSRIs) in the 
late 1980s. This rise is primarily due to general 
practitioners (GPs) continuing to prescribe 
for longer,1 2 with the average length of treat-
ment now at more than 2 years.3 4 Around 
10% of adults are currently taking antidepres-
sants (predominantly for depression, but also 
for anxiety and chronic pain).5 Some people 
need long-term antidepressants to prevent 
relapse, but surveys suggest 30%–50% have 
no guideline-based indication for long-term 
use (eg, according to National Institute for 
Health and Care Excellence  (NICE) Depres-
sion Guideline (2009)).6–8 This may be due 
to many patients on long-term treatment 
being given repeat prescriptions and being 
reviewed infrequently.9 10 
The side effects of antidepressants include 
weight gain, sexual dysfunction, sleep distur-
bance and gastrointestinal bleeding, which 
increase with longer term use.11 SSRI use 
for depression in older patients is associ-
ated with increased risk of falls, fractures, 
seizures, stroke and hyponatraemia.12 Long-
term treatment may lead to emotional 
blunting,13 impaired self-confidence and 
increased dependence on health services. 
Antidepressants constitute a substantial 
proportion of the National Health Service 
(NHS) drug budget: 2.5% in 201014 and 
the costs of unnecessary treatment include 
appointments for medical or nursing reviews. 
The cost of GP consultations for depression 
exceeded £30 million in 2008, in addition to 
the cost of the 64.7 million antidepressant 
prescriptions of around £266 million.15–17 
Attempts to discontinue in the 30%–50% 
of patients taking antidepressants without 
guidance-based indication may then result in 
reduced NHS costs while alleviating the side 
effects associated with antidepressant use.
strengths and limitations of this study
 ► This study explored the views of primary care health 
professionals (HPs)  in relation to antidepressant 
withdrawal.
 ► Focus groups allowed participants to exchange 
views on the topic thereby providing topic-rich data.
 ► Unlike previous research, this study included per-
spectives of non-general practitioner HPs.
 ► The use of focus groups facilitated group discussion; 
however, it is possible that the group setting may 
reduce openness.
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Prompting GPs to review patients eligible for with-
drawal was tested in a trial in the Netherlands and found 
to be ineffective, with 6% of patients discontinuing anti-
depressants in the intervention group and 8% in the 
control group.18 Similarly, an uncontrolled trial of phar-
macist-prompted GP review of long-term users in Scot-
land resulted in only 7% of people stopping.3 Prompting 
alone is therefore insufficient in supporting patients to 
discontinue antidepressants, which indicates there are 
other factors preventing GPs from attempting to with-
draw patients from antidepressants.
While GPs play a key role in prescribing and discon-
tinuing antidepressants, other health professionals 
(HPs) also advise patients about antidepressants in 
primary care. Previous research with HPs looking at anti-
depressant discontinuation has reported that the main 
barrier is a lack of awareness of guidance on best prac-
tice in discontinuation.19 Other barriers include a lack of 
awareness of patient expectations that HPs should initiate 
discussions of discontinuation, the availability of alter-
native treatments, time constraints, and GP and patient 
fear of destabilising a currently well patient.19 20 Further 
to this, patients may experience withdrawal symptoms or 
relapse and require further treatment from their practi-
tioner.21 A qualitative metasynthesis of patient and prac-
titioner's perspectives on antidepressant discontinuation 
highlighted a lack of consistent support and guidance 
for GPs and the impact of time constraints on discontin-
uation.22 However, there is only limited evidence on the 
HP's perspective of antidepressant discontinuation (in 
particular practice nurses and community mental health 
workers), and previous studies were completed outside of 
the UK, and one within a nursing home. Insights into UK 
primary care HP's perspectives are therefore needed to 
determine barriers and facilitators to supporting patients 
in discontinuing antidepressants in the UK.
The REviewing long term anti-Depressant Use by Careful 
monitoring in Everyday practice (REDUCE) programme 
aims to identify ways of helping patients taking long-term 
antidepressants withdraw from treatment when appro-
priate.23 Normalisation Process Theory (NPT) identifies, 
characterises and explains key mechanisms that motivate 
and shape implementation processes.24 It focuses attention 
on the work that participants in these processes do when 
they seek to routinely incorporate components of complex 
interventions in their everyday lives. This paper reports the 
findings from the HP focus groups as part of the REDUCE 
programme. Our aims were to identify, characterise and 
explain clinician factors that shape decision-making around 
antidepressant discontinuation in UK primary care.
MethODs
Participants
HPs including GPs, GP assistants, nurses, community 
mental health team workers and psychotherapists were 
recruited from seven primary care regions and two NHS 
Trusts providing community mental health services 
in the South of England between January and May 
2017. GP practices and individuals were recruited via 
email and were invited to return a reply slip. HPs who 
expressed an interest were invited to take part in one of 
four focus groups taking place in the South of England 
between March and May 2017. Twenty-one sites returned 
a reply slip, with 38 participants taking part in either a 
focus group or interview (22 females, 12 males, and four 
participants for whom demographic information was not 
provided). The reported range of years since qualified 
was 8–34. Focus groups were chosen over individual inter-
views to allow participants to exchange views on the topic 
thereby providing topic rich data as well as an insight into 
group and individual views, including important areas of 
consensus and disagreement. Individual interviews were 
offered to psychotherapists as this group was under-rep-
resented in the focus group sample (n=2) and to one GP 
in order to pilot the topic guide. Every participant was 
taken through the informed consent process and given 
the opportunity to read the information leaflet and ask 
questions prior to data collection. Each focus group had 
between 7 and 10 participants, and the length of each 
ranged between 43 and 59 min.
Patient and public involvement
Patient and public members of the REDUCE team were 
involved in discussions about the design and recruitment 
for this study, and were invited to comment on initial 
drafts of the topic guide.
Focus groups
A topic guide was developed based on the main aims of 
the study (online supplement 1). This guide was devel-
oped based on a review of existing literature and discus-
sion within a team of academics, GPs, psychiatrists and 
patient contributors. Topics explored long-term anti-
depressant use and knowing when discontinuation may 
be appropriate, negotiating the decision to discontinue 
antidepressants with patients, HP roles in supporting 
and negotiating appropriateness of discontinuation, 
optimising discussions about possible discontinuation 
and optimising implementation of a discontinuation 
intervention in routine practice. NPT24 informed the 
topic guide so that the questions addressed the processes 
involved in antidepressant discontinuation with regard 
to the four NPT constructs (coherence, cognitive partic-
ipation, collective action and reflexive monitoring). For 
example, to address cognitive participation (ie, who does 
the work), participants were asked ‘What do you see as 
your role in negotiating medication discontinuation’. 
The topic guide was not limited to discussing depressive 
disorders and therefore was open to discussion about 
antidepressant use in other conditions (eg, anxiety and 
chronic pain).
The focus groups were conducted face-to-face and were 
organised pragmatically across different geographical 
locations (in GP practices and a community-based health 
centre) in the South of England. Two groups were held 
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with mixed primary care HPs and two groups with GPs 
only (see table 1). To acknowledge potential ‘group’ 
effects (ie, participants being unaware of the degree to 
which other group members’ views represent their own 
experience), free participation was encouraged by the 
facilitators by avoiding censorship and conformity.25 
Focus groups were facilitated by two experienced female 
qualitative researchers (SJW and WOB) and were audio 
recorded. A debriefing was conducted by the two facili-
tators following each focus group to identify issues that 
may affect analysis (eg, domineering or quiet members) 
and suggest possible modifications to the topic guide. No 
repeat interviews or focus groups were conducted.
Interviews
Three semistructured face-to-face qualitative interviews 
were conducted with two psychotherapists and a GP. 
The same topic guide that had been developed for the 
focus groups was used in the interviews to ensure consis-
tency. As with the focus groups, the interviewer explored 
additional topics when brought up by the interviewee. 
Interviews were carried out by an experienced qualitative 
researcher (SJW) and were audio recorded.
Analysis
All focus groups and interviews were transcribed verbatim. 
Transcripts were read and re-read by SJW both during and 
after the data collection period. While the focus groups 
and interviews were taking place, the REDUCE Study 
team met regularly to discuss topics raised by participants, 
and the topic guide was refined as the focus groups and 
interviews progressed through debriefing with the two 
facilitators and through meetings with the wider research 
team. These discussions resulted in only minor changes 
regarding the order and wording of questions.
A thematic analysis approach was used to analyse data 
drawing on methods of constant comparison.26–29 SJW 
independently coded the seven transcripts using NVivo, 
and a secondary analysis team (SJW, AWAG, HMB, GL 
and TK) met to agree a preliminary coding frame, which 
was then agreed by the whole team. HMB independently 
coded two transcripts using the coding frame; discrepan-
cies were minor and changes were made following discus-
sion with the team. Codes were grouped into themes by 
SJW and HMB, where both within and between-participant 
variation was considered. Theme labelling and interpre-
tation were continually discussed in regular team meet-
ings. Data were assessed for saturation by SJW individually 
and across-group.30 Data saturation was determined when 
no new codes were emerging.
results
Five themes were identified from the data analysis 
regarding barriers and facilitators to discussing antide-
pressant discontinuation with patients (see figure 1).
theme 1: who is responsible for broaching the subject of 
discontinuation?
There were differing views about who is responsible for 
raising the topic of discontinuation in a consultation. A 
small number of HPs suggested it was the patient’s respon-
sibility to broach the subject and that this expectation 
should be set when antidepressants are first prescribed.
I tend to say to people, 'Look, when you start it, I'd 
like you to continue for at least six months after 
you've felt well', and then right at the outset, I put 
the responsibility over to them and say, 'Look, one 
of the things about depression is that you lose con-
trol and the worst thing is to come to see the doctor 
and the doctor takes over control. So, as far as I'm 
concerned, you're in control of these tablets and it's 
your choice as to when you want to stop it but usually 
the recommendation is six months after you've been 
well'. I think most people—I haven't audited it—at 
that stage, do come back round about six months-
ish and are keen to stop and usually that works okay. 
(GP/09/0002)
One GP argued in favour of telling the patient at the 
initial prescription that they have the responsibility to 
initiate stopping and the choice to discontinue is up to 
them. By setting this expectation, it opens up the possi-
bility of them taking control by broaching the subject 
with their GP when they are ready.
However, HPs highlighted there are problems with 
relying on the patient to broach the issue. Two nurses 
and a psychotherapist acknowledged that many patients 
may not instigate these conversations. One psychother-
apist explained that patients may be reluctant to broach 
Table 1 Number of health professionals attending each focus group or interview
Focus group 1 Focus group 2 Focus group 3 Focus group 4 Interview Total (n female)
GP 7 2 2 9 1 21 (10)
GPA 0 4 0 0 0 4 (3)
NP 0 2 5 0 0 7 (6)
CMHW or PT 0 2 2 0 2 6 (3)
Total 7 10 9 8 3 38
CMHW, community mental health team worker; GP, general practitioner; GPA, general practitioner assistant; NP, nurse practitioner; PT, 
psychological therapist.
 o
n
 25 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027837 on 4 July 2019. Downloaded from 
4 Bowers HM, et al. BMJ Open 2019;9:e027837. doi:10.1136/bmjopen-2018-027837
Open access 
the subject due to expectations of how the doctor may 
respond, or perceiving the doctor to be more knowledge-
able about the situation.
Even if they do get an appointment, I've met a lot 
of people who are really hesitant about asking about 
changes in medication, because of the response from 
the doctor perhaps or their perceived response… I 
think there's often a worry, you know, the kind of, 
'Doctor knows best, and they put me on this medi-
cation. So I don't want to offend or I don't want to 
question’. (PT/14/0002)
One GP suggested that when patients do not raise the 
idea of discontinuation, practitioners may assume that the 
patient wants to continue treatment. This mutual assump-
tion that the HP wants the patient to continue, and that 
the patient him/herself wants to continue, may result in a 
form of collusion to maintain the status quo.
HPs appeared to be aware that relying on the patient 
to initiate discussion may be problematic, as evidenced 
through the way some HPs discussed the problem. It may 
therefore follow that the responsibility to initiate discus-
sions about discontinuation should lie with the GP.
I think I'm guilty of this, it's very easy just to keep 
kicking the can down the road and the patient keeps 
taking the medication because they feel they should 
and you keep prescribing it because you assume they 
still want it and there's this kind of collusion that un-
less you actively intervene and say, 'Come and talk to 
me', or whatever. (GP/11/0001)
Some participants (including GPs) thought that it was 
the GP’s responsibility to broach the subject with patients; 
arguing that the person who prescribes the medication 
should be the person to initiate discussion of discontin-
uation. This was especially the case if a patient has been 
on the medication long term and may not have consid-
ered stopping. However, taking a proactive approach 
was not always considered feasible in practice; continuity 
may facilitate discussions of antidepressant withdrawal, 
although it is not always possible in primary care.
Some of the HPs referred to the discussion of discon-
tinuation as a shared decision process. They talked about 
the need to assess the patient’s capacity in making deci-
sions about withdrawal and negotiating with the patient 
to come to a shared decision about whether to discon-
tinue. One GP also suggested it must be a shared deci-
sion as GPs are currently unable to manage the amount of 
work involved due to organisational factors which make 
having these conversations more challenging.
We'd say that because these patients are working and 
living in the community and are not sectioned and 
have capacity, that there is definitely a shared respon-
sibility with the patient because it is their medicine 
and their mental health that we're looking after. So 
I'm quite happy to say it's a shared responsibility but 
it definitely can't be just a primary care clinician's be-
cause we'll not manage to cope. (GP/19/0002)
The role of other HPs was also discussed with regard 
to conversations around discontinuing antidepressants. 
Although nurses have been considered to play a role in 
these discussions, there is acknowledgement that there 
are limitations regarding their authority and experience 
in managing medications, and often patients are sign-
posted to their GP by their nurse. Social workers, phar-
macists, care coordinators and psychiatrists were also 
mentioned as potential sources of additional support in 
stopping antidepressants, in some cases.
theme 2: risk of destabilising current situation
Some HPs described it being easier to continue prescribing 
rather than raising discontinuation with patients and 
acknowledged a need to initiate more discussions about 
discontinuation with patients who may be eligible. There 
were concerns about instigating discussions with patients 
Figure 1 Diagram of the relationships between themes.
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who are currently well as they did not want to risk destabi-
lising the current situation. It was considered less risky to 
continue prescribing.
I think about—not just to patients but also to health-
care professionals or GPs—to reduce the medica-
tion is the concern that they might be working and 
reducing might destabilise a current stable situation, 
especially if the patient has been very, very difficult 
to control in the past and hasn't got the support net-
work perhaps. (GP/12/0001)
There was an assumption that patients also do not want 
to risk upsetting the current situation if they are feeling 
well.
I think for a lot that are on them, there is a massive fear 
factor about stopping, because they remember how 
awful they felt. They don't want to feel like that. They 
feel well again and they just think, well, you know, I'd 
rather just keep the status quo. (GP/03/0004)
theme 3: continuity and knowing the patient makes it easier 
to discuss discontinuation
Involvement in the initial prescription was perceived to 
place responsibility on the prescriber to prompt discon-
tinuation later, and an opportunity to discuss and set 
patient expectations around withdrawal. Explaining to a 
patient at the initial prescription that discontinuation will 
be discussed at a later date was seen to be a facilitator in 
broaching the subject of discontinuation.
The very first consultation if you’re actually selling 
the idea of some medication being helpful, that it’s 
for a specific time period, expecting someone to be 
able to be able to come off it at about six months, so 
suggest your timescale of appointments and then say, 
‘Oh, see you in about five months from the initiation 
of treatment. At that point, we can actually make a 
plan for withdrawal and I would be planning to with-
draw it slowly if everything was going well in your life’. 
(GP/11/0004)
There were a number of facilitators to discussing discon-
tinuation with patients. These included knowledge of the 
patient’s experience with antidepressants, their triggers 
for depression, why they started their medication and 
how things have changed since the initial prescription. 
This again suggests that continuity is beneficial, especially 
in terms of reducing risk.
theme 4: a hP’s confidence in their skills and knowledge
Some of the HPs reported a lack of confidence, knowl-
edge and skill with regards to antidepressant discontinua-
tion which could act as a barrier to broaching the subject 
of stopping with patients. There was an awareness that 
discussing discontinuation with patients is something that 
could be improved on.
As a GP, I think for GPs, I think we're very good at 
starting patients on it. We are good at titrating the 
dose up. Pretty good at picking the right medica-
tions suitable for the patients, because they have 
different side effects over spectrums. But what we're 
probably not good enough, at the moment, is sort 
of the long-term managing and the coming-off part. 
(GP/12/0001)
HPs discussed a need for more support and informa-
tion for themselves as well as for patients. They spoke 
about NICE guidance on antidepressant discontinuation, 
with many being unfamiliar with the guidance or not 
using them. They described being dissatisfied and, in one 
case, irritated by the current guidance. They highlighted 
that it is unclear (especially regarding tapering regimes), 
limited, not accessible and at times not applicable to real 
patients.
I don't think there's a lot of resources out there to 
kind of what to say and how to do it. I'm sure I've 
looked at the guidelines before and I thought a bit 
pants. (NP/12/0001)
theme 5: organisational barriers and enablers to discussing 
discontinuation
The above processes are shaped by the context 
surrounding them, with environmental work contrib-
uting to decision-making around discontinuation. Some 
aspects of the healthcare system were described as further 
barriers to antidepressant discontinuation. A lack of 
continuity was reported with patients seeing different 
practitioners each time, and these practitioners were at 
times providing inconsistent recommendations. This may 
act as a barrier to discussing discontinuation due to the 
perceived need to be familiar with a patient to discuss 
withdrawal, and the idea that the responsibility for raising 
the topic of discontinuation lies with the HP who initially 
prescribed the antidepressant.
HPs repeatedly noted the challenge of time constraints 
in practice and how this is often a barrier to both initi-
ating and managing discontinuation due to ten minute 
consultations not being long enough, and not having the 
time for review appointments.
Things are ticking along relatively okay, you know 
it's not going to be necessarily a straightforward con-
sultation and it might be time consuming, it might 
delay you and you haven't got enough appointments 
anyway and da, da, da, da, you can see how that, as 
a clinician, restrains you from perhaps rocking the 
boat. (GP/11/0002)
HPs also mentioned the role of computer systems, 
explaining that patients can get lost in the system and 
that systems which adequately prompt medication reviews 
would be useful in broaching discontinuation with 
patients.
DIsCussIOn
In this paper we explored HP's perspectives on discon-
tinuing long-term antidepressants in primary care. Five 
 o
n
 25 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027837 on 4 July 2019. Downloaded from 
6 Bowers HM, et al. BMJ Open 2019;9:e027837. doi:10.1136/bmjopen-2018-027837
Open access 
themes were identified and covered who is responsible 
for broaching the subject of discontinuation, how fear 
of relapse can dissuade HPs from discontinuing, famil-
iarity with the patient as enabling conversations around 
withdrawal, the lack of information and support for HPs, 
and organisational barriers and enablers. With regard to 
NPT,24 there is relational work that goes into negotiating 
responsibility and shared decision-making about antide-
pressant discontinuation. This relational work is founded 
on familiarity with the patient and knowledge of their 
experiences with depression and antidepressants. There 
is process work that goes into intervening, managing the 
consequences of withdrawal and avoiding destabilisation 
of a patient during and following discontinuation. This 
is founded on enacting generalisable clinical knowledge 
and practice with confidence. These processes are then 
shaped by contextual mechanisms and there is environ-
mental work that goes into negotiating the decision to 
discontinue antidepressants.
An important theme identified in the current paper is 
contention in terms of who is responsible for broaching 
the topic of discontinuation. While the majority of HPs 
acknowledged that the responsibility may lie with the GP 
or be a shared decision with patients, they indicated that 
they currently do not initiate these conversations as much 
as they feel they ought to. There is limited evidence of 
this in previous research with one study reporting that 
some GPs expect patients to contact their practitioner 
when they wish to make changes to or discontinue their 
antidepressant.19
The shift in recent decades in primary care towards 
expert patients and self-care relies on an expectation of 
agency on behalf of the patient.31 However, depression 
and the long-term use of antidepressants are associated 
with reduced agency.32 HPs appear to be aware that there 
are barriers for patients in initiating conversations about 
withdrawal. The logical implication of this would be that 
GPs take the responsibility for initiating these conversa-
tions. However, despite GPs’ awareness of the need to 
improve on the current situation, these conversations 
about discontinuation are often not routinely being 
initiated.
GPs in the current study discussed a tension between 
being more proactive in their role and their full workload, 
which limits opportunities to demarcate time for focused 
discussion about discontinuation. Among the factors 
enabling discussion about discontinuation were knowing 
the patient and continuity of care. However, in current 
UK primary care, patients do not always see the same GP 
and GPs therefore may be unable to build the desired 
relationship with or acquire the desired knowledge of a 
patient before broaching the subject of stopping antide-
pressants. The way primary care often operates therefore 
does not lend itself to the desired context for discussing 
withdrawal, which results in a bias towards inaction. One 
implication is that familiarisation with the patient’s situ-
ation should be achieved through medical notes and 
discussion with the patient. However, time constraints 
may mean that consultations are not long enough to 
gather the desired information before discussing with-
drawal. If it were agreed that initial discussions should 
be triggered by the GP, this would bring clarity to the 
currently uncertain system. With a more clearly articu-
lated plan, GPs may be better able to arrange appoint-
ments (perhaps double appointments where necessary) 
to discuss discontinuation.
HPs reported fear of destabilising currently well 
patients by discontinuing antidepressants; a fear which 
has been evidenced in patients and GPs.19 20 33 This 
emphasis on avoiding negative outcomes over focusing 
on the longer term benefits of discontinuation may result 
in a preference for deferring discussions of withdrawal. 
However, when comparing antidepressant maintenance 
treatment to tapering with psychological support, long-
term relapse rates for depression are comparable34–36 or 
in some cases lower for patients receiving psychological 
therapy.37 38 It may therefore be useful to reassure HPs 
that the risk of relapse may be minimised if discontin-
uation is accompanied by appropriate psychological 
support (although there is still a need for further work 
on providing support for patients who are discontinuing 
antidepressants).34 38 39
HPs report dissatisfaction with the current guidelines 
and acknowledge gaps in their own knowledge regarding 
antidepressant withdrawal. One other study has high-
lighted that GPs feel guidelines could provide more 
specific information about antidepressant treatment 
and discontinuation.19 This suggests a need to provide 
improved guidance and enhanced accessibility to and 
awareness of guidance on discontinuation, including 
specific guidance on reducing the doses of different anti-
depressants. This may increase HP confidence in their 
ability to support patients through discontinuation. This 
increased confidence in the HP ability to manage discon-
tinuation may then also help to lessen the HP’s fears 
around destabilisation and relapse.
strengths and limitations
This study is the first to explore HP's perspectives of 
antidepressant discontinuation in UK primary care, 
with its larger sample consisting of a range of HP roles 
(including GPs, GP assistants, nurses, community mental 
health team workers and psychotherapists) which were 
lacking in previous research,20 21 33 40 41 and data reached 
saturation. GPs were the largest group among our inter-
viewees, compared with the other professionals, which 
aligns with the current prescribing activity with the large 
majority of long-term antidepressants prescribed and 
monitored by GPs. This fits with our finding that GPs 
are often considered responsible for initiating conversa-
tions around withdrawal. However, we also identified that 
there are a number of professionals who may be involved 
in discontinuation (eg, pharmacists, social workers and 
care coordinators) and further research may be needed 
to explore these perspectives. For example, none of the 
practices in the current study managed discontinuation 
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using practice pharmacists, who may play an important 
role in antidepressant withdrawal. In particular, it may be 
of interest to explore differences between professions.
The use of focus groups facilitated discussion and 
provided candid responses from participants. However, it 
is possible for discussions to become polarised or influ-
enced by dominant members of the group. For example, 
in a focus group of nine GPs, there were two more 
dominant members and two members who spoke less 
frequently. As such, some participants’ views may be less 
well represented in a group setting. Giving participants 
an opportunity to provide feedback on the study’s find-
ings might have helped provide greater representation.
COnClusIOn
Previous research has highlighted time constraints and 
fear of relapse as barriers to GPs discontinuing antide-
pressants and one previous study found that some GPs 
expected patients to initiate discussions of discontinu-
ation. The current study has explored these barriers in 
detail in UK primary care health professionals and high-
lighted additional factors influencing decisions around 
discontinuation such as organisational barriers, a need 
for clearer guidance and a desire to know the patient well. 
Our findings highlight a need to support HPs in antide-
pressant discontinuation in terms of providing specific 
information and guidance on how to discontinue anti-
depressants. They also suggest HPs would benefit from 
support and guidance around fears of patient relapse and 
awareness of the need to initiate discussions about discon-
tinuation. These findings have informed intervention 
development within the REDUCE programme. Future 
research is needed to explore ways in which HPs can be 
supported in managing antidepressant discontinuation 
in primary care and in a way that is acceptable and effec-
tive for patients.
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